Unfortunately Allan Robins is unable to be with us Progress to Therapy 2012. However, in his place, we will now welcome Dr Olivia Kelly, current Director of Cell Biology at Viacyte Inc. We are very grateful and excited to welcome Olivia to Glasgow and have her discuss her topic of ES Derived Islets to Treat Type I Diabetes with us on day three.
29 February 2012
P2T Fully Accredited By Royal College of Physicians
Good News!
All three days of the Progress to Therapy 2012 conference have now been CPD accredited.
All three days of the Progress to Therapy 2012 conference have now been CPD accredited.
28 February 2012
CPD Accreditation Applied For...
Progress to Therapy 2012 is currently in the process of obtainting CPD accreditation for its three day conference in March.
Hurry, last chance to reserve your place at this conference before registration closes on Friday....
Hurry, last chance to reserve your place at this conference before registration closes on Friday....
14 February 2012
New Speakers Added to Agenda
Dr John Purves is a life science consultant having recently
retired from the European Medicines Agency (EMA) where he worked for 14 years,
as head of sector for the quality of medicines, including classic biological
and biotechnology products. He has been involved in the development of
legislation, guidelines and of the review procedures for dossiers submitted in
support of applications for Marketing Authorisations in many areas dealing with
such products, including recombinant-DNA, biosimilar, influenza and advanced
therapy products.
Prior to joining the EMA, Dr Purves was manager of the
biotechnology and biological unit, for 21 years, at the UK Medicines Control
Agency, now the Medicines and Healthcare products Regulatory Agency. At the UK
agency, he was involved in the drafting of some legislation, and of a number of
supportive European Union guidelines, dealing with the manufacture and control
of recombinant-DNA products and products derived from human blood and plasma.
Dr Purves also oversaw efforts to minimise the risk of the transmission of
spongiform encephalopathies to humans through medicinal products.
Dr Christian van den Bos serves as Executive Program
Manager at Lonza and drives Lonza’s development efforts for advanced stem cell
products.
Dr van den Bos has over 15 years of experience in cell therapy
work and has managed cell therapy projects ranging from early R&D to
production, regulatory and clinical trials.
Prior to joining Lonza he served as Sr. VP, EU
Affairs for Cytograft, USA, as Head of Development and Operations for Symetis,
Switzerland &Germany, as VP of R&D for Viacell Europe, Germany, as
Director, Biologics, for Spectra Stable Isotopes/Martek Biosciences, USA and as
Sr. Scientist for Osiris Therapeutics, Baltimore, Maryland.
Dr Gert De Beckker is Head Regulatory Affairs at TiGenix NV, a late stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. In the past 2.5 years he was responsible for the centralized marketing authorization application of ChondroCelect a cell based therapy. This lead product of Tigenix was granted marketing authorization on October 5th 2009.
Dr Gert De Beckker is Head Regulatory Affairs at TiGenix NV, a late stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. In the past 2.5 years he was responsible for the centralized marketing authorization application of ChondroCelect a cell based therapy. This lead product of Tigenix was granted marketing authorization on October 5th 2009.
9 February 2012
Last Two Days to Register for P2T at Reduced Early Bird Rate
The early bird rate for P2T 2012 is coming to an end on Friday, Feb 10th. This is your last chance to register at this reduced rate for this three day conference in Glasgow (March 21st - 23rd), bringing together international experts to share knowledge and experience with the aim of accelerating Progress to Therapy in Regenerative Medicine.
Subscribe to:
Posts (Atom)